Evotec and Sandoz Advance Partnership with Potential Toulouse Site Sale

Evotec SE and Sandoz AG have signed a non-binding agreement for the potential sale of the Just – Evotec Biologics facility in Toulouse. This proposed deal would see Evotec transferring its biosimilar manufacturing capabilities to Sandoz. The transaction is valued at approximately $300 million, with additional revenue opportunities tied to technology, development, and royalties. This move aligns with Evotec's strategy to adopt a capital-efficient, asset-light model and is expected to improve their revenue mix and profit margins.

The facility in Toulouse has been dedicated to Sandoz since mid-2024, marking this move as a natural progression in their strategic collaboration. As part of the agreement, Sandoz will gain access to Evotec's proprietary continuous manufacturing technology. The transaction awaits regulatory approval and completion of consultation processes, expected by the end of the year.

Evotec's leadership sees this as a key milestone for the company, underlining their shift towards leveraging technology to enhance service offerings. The transaction represents an opportunity to reshape the biologics manufacturing market while maintaining economic benefits through ongoing revenue streams.